

HEALTH AND MEDICINE

Twofold improved tumor-to-brain contrast using a novel T1 relaxation-enhanced steady-state (T₁RESS) MRI technique

R. Edelman^{1,2*}, N. Leloudas¹, J. Pang³, J. Bailes^{4,5}, R. Merrell^{4,6}, I. Koktzoglou^{1,4}

A technique that provides more accurate cancer detection would be of great value. Toward this end, we developed T1 relaxation-enhanced steady-state (T₁RESS), a novel magnetic resonance imaging (MRI) pulse sequence that enables the flexible modulation of T1 weighting and provides the unique feature that intravascular signals can be toggled on and off in contrast-enhanced scans. T₁RESS makes it possible to effectively use an MRI technique with improved signal-to-noise ratio efficiency for cancer imaging. In a proof-of-concept study, “dark blood” unbalanced T₁RESS provided a twofold improvement in tumor-to-brain contrast compared with standard techniques, whereas balanced T₁RESS greatly enhanced vascular detail. In conclusion, T₁RESS represents a new MRI technique with substantial potential value for cancer imaging, along with a broad range of other clinical applications.

Copyright © 2020
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim to
original U.S. Government
Works. Distributed
under a Creative
Commons Attribution
License 4.0 (CC BY).

INTRODUCTION

Contrast-enhanced magnetic resonance imaging (MRI) is the cornerstone for brain tumor diagnosis (1). While its sensitivity for metastases is superior to that of computed tomography (CT) or positron emission tomography–CT, small lesions (<5 mm) may still be missed, which can have a major impact on prognosis and treatment planning for stereotactic radiosurgery (2, 3). Triple-dose contrast administration can increase sensitivity but is seldom used because of concerns about nephrogenic systemic fibrosis (4). A method that could further improve the sensitivity and specificity of MRI for tumors would be of great clinical benefit. Toward this end, we have developed a new MRI pulse sequence, called T1 relaxation-enhanced steady-state (T₁RESS), that improves the visibility of tumors in contrast-enhanced MRI by differentially suppressing the signal intensity of nonenhancing background tissues while maintaining the signal intensity of contrast-enhancing lesions. Two variants of T₁RESS were implemented (Fig. 1A). One version, which we call “balanced” T₁RESS (bT₁RESS), uses a readout in which the gradient moments are fully balanced to make contrast-enhanced blood vessels appear bright. A second “unbalanced” T₁RESS (uT₁RESS) version renders blood vessels dark by using a steady-state readout in which the gradients are unbalanced.

RESULTS

For both versions of T₁RESS, the periodic application of contrast-modifying radio frequency (RF) pulses was essential for generating T1 contrast (Fig. 1B) and suppressing the signal intensity of cerebrospinal fluid (Fig. 2, A and B). bT₁RESS outperformed spoiled gradient echo (GRE) for creating angiographic renderings in which the blood

vessels appeared bright (movie S1), whereas uT₁RESS rendered the blood vessels uniformly dark (Fig. 2C).

For imaging of tumors, the bland, low-signal background and sensitivity to lesion enhancement resulted in a marked improvement in the visibility of enhancing tumors compared with standard pulse sequences. With uT₁RESS, enhancing tumors appeared particularly conspicuous against a background in which blood vessels along with nonenhancing tissues all appeared relatively dark (Fig. 3). With this method, we found that even minute metastatic tumor deposits that were difficult to distinguish from small blood vessels using three-dimensional (3D) spoiled GRE could be unambiguously identified (Figs. 4 and 5). Moreover, banding artifacts from off-resonance effects were absent with uT₁RESS, whereas they were often seen near air–soft tissue boundaries with bT₁RESS.

Quantitative comparisons demonstrated that bT₁RESS significantly outperformed both 3D spoiled GRE and 3D inversion recovery (IR) spoiled GRE (IR-SPGRE) imaging with respect to vessel visibility. In 40 patients, the mean signal-to-noise ratio (SNR) of the superior sagittal sinus was 1.49-fold better with bT₁RESS versus 3D spoiled GRE (359.43 ± 137.30 versus 241.27 ± 80.47 , $P = 3.26 \times 10^{-7}$), while the mean vessel-to-brain contrast was improved by a factor of 2.04 (2.46 ± 0.53 versus 1.21 ± 0.33 , $P = 3.57 \times 10^{-8}$). Both T₁RESS versions outperformed 3D spoiled GRE and 3D IR-SPGRE with regard to tumor visibility, as gauged by tumor-to-brain contrast and contrast-to-noise ratio (CNR). For brain tumors (88 tumors in 40 patients), the mean CNR of brain tumors with respect to normal parenchyma was significantly better for bT₁RESS versus 3D spoiled GRE (133.15 ± 100.81 versus 53.53 ± 51.15 , $P = 1.48 \times 10^{-14}$), as was the tumor-to-brain contrast (1.25 ± 0.68 versus 0.51 ± 0.39 , $P = 7.21 \times 10^{-15}$). Comparing uT₁RESS with 3D spoiled GRE (84 tumors in 38 patients), the respective values for mean CNR of brain tumors were 105.80 ± 80.26 versus 54.84 ± 51.44 ($P = 2.59 \times 10^{-13}$), the respective values for mean tumor-to-brain contrast were 1.37 ± 0.74 versus 0.51 ± 0.39 ($P = 1.12 \times 10^{-14}$), and the respective values for mean tumor-to-blood vessel contrast were 1.74 ± 1.07 versus -0.29 ± 0.17 ($P = 2.05 \times 10^{-15}$). Comparing uT₁RESS with 3D IR-SPGRE (45 tumors in 22 patients), the respective values for mean CNR of brain tumors were 164.37 ± 97.21 versus 100.45 ± 86.45 ($P = 7.62 \times 10^{-6}$), the respective values for mean tumor-to-brain

¹Radiology, NorthShore University HealthSystem, 2650 Ridge Ave., Evanston, IL 60201, USA. ²Northwestern Medicine, 251 E. Huron St., Chicago, IL 60611, USA. ³Siemens Medical Solutions USA Inc., 737 N. Michigan Ave., Chicago, IL 60611, USA. ⁴University of Chicago Pritzker School of Medicine, 924 E. 57th St., Chicago, IL 60637, USA. ⁵Neurosurgery, NorthShore University HealthSystem, 2650 Ridge Ave., Evanston, IL 60201, USA. ⁶Neurology, NorthShore University HealthSystem, 2650 Ridge Ave., Evanston, IL 60201, USA.

*Corresponding author. Email: redelman999@gmail.com




Fig. 1. T₁RESS pulse sequence. (A) Pulse sequence diagram using balanced (top) and unbalanced (bottom) steady-state readouts. α represents the imaging radio frequency (RF) pulse, and FS denotes the fat saturation RF pulse. A nonspatially selective contrast-modifying RF pulse ($CM\alpha$) is applied periodically over the entire duration of the echo train to introduce an arbitrary amount of T₁ weighting. For brain imaging, $CM\alpha$ TR \approx 400 ms. Note that store/restore RF pulses (represented by $\alpha/2$) are needed for balanced T₁RESS, but not for the unbalanced version. ADC, analog-to-digital conversion. (B) Phantom consisting of serial dilutions of gadobutrol imaged with bT₁RESS using $CM\alpha$ values of 0°, 30°, and 60°. T₁ relaxation times in millisecond units are shown in the lowest frame. Note that there is negligible T₁ contrast for a $CM\alpha$ flip angle of 0°, but substantial T₁ contrast is apparent as the flip angle is increased to 60°.

contrast were 1.69 ± 0.89 versus 0.82 ± 0.55 ($P = 5.14 \times 10^{-8}$), and the respective values for mean tumor-to-blood vessel contrast were 2.56 ± 1.21 versus -0.15 ± 0.34 ($P = 5.54 \times 10^{-9}$).

uT₁RESS also provided markedly superior tumor-to-brain contrast and CNR compared with T₁ 3D variable flip angle fast spin echo (3D-VFA-FSE) (Fig. 6). Comparing uT₁RESS with T₁ 3D-VFA-FSE (32 tumors in 14 patients), the respective values for mean CNR of brain tumors were 180.32 ± 92.34 versus 60.34 ± 54.88 ($P = 8.75 \times 10^{-7}$), the respective values for mean tumor-to-brain contrast were 1.76 ± 0.76 versus 0.89 ± 0.43 ($P = 7.95 \times 10^{-7}$), and the respective values for mean tumor-to-blood vessel contrast were 2.58 ± 1.21 versus 11.94 ± 5.26 ($P = 7.95 \times 10^{-7}$).

DISCUSSION

Several types of MRI pulse sequences are routinely used in clinical practice. The most common include spin echo and its rapid variant, fast spin echo (5); spoiled GRE (6); and balanced steady-state free precession (SSFP) (bSSFP) (7). For oncological applications of MRI, T₁ weighting is essential to detect tumor enhancement from paramagnetic contrast agents (8). The spoiled GRE sequence provides excellent T₁ weighting and is efficient with respect to scan time because it allows the use of short repetition times (TR). Volumetric implementations such as 3D IR-SPGRE have become essential components of cancer imaging protocols for the brain and other organ systems (9). However, spoiled GRE-based techniques have low SNR efficiency as they are restricted to using a low flip angle RF excitation (on the order of the Ernst angle of the tissue of interest) to avoid excessive depletion of the longitudinal magnetization (10). Like spoiled GRE, bSSFP also permits the use of very short TR. Unlike spoiled GRE, bSSFP can effectively use a large flip angle RF excitation due to its recycling of transverse magnetization, which results in the highest SNR efficiency of any MRI sequence (11).

With bSSFP, the image contrast is almost entirely determined by the ratio of the T₂ and T₁ relaxation times (11, 12). Consequently, tissues with a high T₂/T₁ ratio, such as arterial blood, cerebrospinal fluid, and fat, appear bright, whereas those with a low T₂/T₁ ratio, such as white matter and muscle (13), appear dark (14). While this tissue contrast has proven useful for several clinical indications (15–18), its dependence on the T₂/T₁ ratio limits the overall clinical utility of the technique. With respect to imaging of tumors, paramagnetic contrast agents shorten both the T₁ and T₂ relaxation times of enhancing tissues, leaving the T₂/T₁ ratio (and thereby the bSSFP signal intensity) largely unchanged (11). Consequently, despite their potential benefits, it remains problematic to use bSSFP pulse sequences for oncological applications.

The T₁RESS method overcomes these limitations through a re-design of the steady-state pulse sequence architecture. It introduces a flexible degree of T₁ weighting into the sequence while maintaining its excellent SNR efficiency by repeatedly applying additional nonspatially selective partial saturation contrast-modifying ($CM\alpha$) RF pulses throughout the duration of the echo train. The $CM\alpha$ RF pulses can be adjusted independently of the imaging RF pulses. The amount of T₁ weighting can be changed as needed by varying the values for the $CM\alpha$ flip angle and TR, with larger flip angles and shorter TR resulting in more T₁ weighting. For the current study, the typical values for the $CM\alpha$ flip angle and TR were $\approx 75^\circ$ and ≈ 400 ms, respectively.

This pulse sequence redesign has two essential benefits for oncological applications: (i) It makes the T₁RESS method highly sensitive to the T₁ shortening effects of paramagnetic contrast agents, so that enhancing tumors can be well visualized, and (ii) it substantially reduces the signal intensity of nonenhancing background tissues, thereby improving the visibility of those enhancing tumors. The high degree of background signal suppression results from several factors: (i) the repeated application of the $CM\alpha$ RF pulses, which partially




Fig. 2. T₁RESS sequence comparisons in different patients. (A) Patient with a meningioma (red arrows). Left: Unmodified three-dimensional (3D) bSSFP acquisition shows bright signal from cerebrospinal fluid and poor tissue contrast, precluding diagnostic evaluation of the tumor or blood vessels. Middle: With bT₁RESS, cerebrospinal fluid and healthy brain tissue appear relatively dark. There is excellent visibility of the contrast-enhancing meningioma, nasal mucosa, venous sinuses, and their tributaries. Right: With 3D spoiled GRE, tumor visibility and vessel detail are inferior to bT₁RESS. (B) Patient with unremarkable brain MRI. Comparison of axial multiplanar reconstructions from uT₁RESS using CM α flip angles of 0° (left) and 75° (right). As with bT₁RESS, without the effect of a CM α RF pulse, there is poor visualization of contrast-enhancing tissues (e.g., choroid plexuses). (C) Axial maximum intensity projections (24 mm thick) from a patient with an unremarkable brain MRI. Left: bT₁RESS. Middle: uT₁RESS. Right: 3D spoiled GRE. bT₁RESS shows much more vascular detail than 3D spoiled GRE, while uT₁RESS shows extensive suppression of intravascular signals. Because the signals from blood vessels and nonenhancing background tissues are suppressed, contrast enhancement of the extraocular muscles (blue arrows), dura, and choroid plexuses (green dashed arrows) is better shown by uT₁RESS than by the other imaging techniques.

saturates the longitudinal magnetization; (ii) the low T₂/T₁ ratio of healthy brain tissue, which, in combination with the SSFP readout, results in a substantially diminished signal intensity relative to spoiled GRE; and (iii) magnetization transfer effects, which are much greater with T₁RESS than spoiled GRE due to the frequent application of short-duration high flip angle imaging and CM α RF pulses (19).

The balanced version of T₁RESS, which we call bT₁RESS, demonstrated excellent tumor-to-background contrast and CNR. It also provided improved angiographic renderings of blood vessels compared with 3D spoiled GRE or IR-SPGRE. Unfortunately, having contrast-enhanced blood vessels appear bright can be a disadvantage for cancer imaging. Enhancing blood vessels distract from, and potentially may be confused with, enhancing tumors (20). This may be especially problematic for detecting very small tumors and leptomeningeal metastases because of the presence of bright cortical vessels nearby.

Therefore, a second uT₁RESS version was developed to provide a robust solution for this problem.

uT₁RESS renders blood vessels dark by using a steady-state unbalanced GRE readout in which the phase-encoding gradients are rewound and the gradient along the frequency-encoding direction is unbalanced (12, 21, 22). The resultant suppression of intravascular signals is a consequence of flow- and diffusion-related phase dispersion that gradually accumulates with each sequence repetition (23). Because the 3D T₁RESS acquisition uses a very large number ($\approx 40,000$) of sequence repetitions, intravascular phase dispersion is complete, resulting in marked suppression of intravascular signal regardless of vessel orientation. While unbalanced steady-state sequences are known to be more motion sensitive than bSSFP or spoiled GRE (24), we found that motion artifacts were generally mild or absent in our brain studies. This is likely because T₁RESS uses a




Fig. 3. Pulse sequence comparisons in a patient with metastatic melanoma. Axial (top) and coronal (bottom) maximum intensity projections (10 mm thick) are shown to highlight differences in lesion visibility for uT₁RESS (left) and 3D spoiled GRE (right). Small metastatic lesions are much better visualized using uT₁RESS than with 3D spoiled GRE. The combination of twofold improved contrast and suppression of intravascular signals with uT₁RESS is helpful to unambiguously identify small metastases.

very weak dephasing gradient, which, along with the large number of sequence repetitions, ensures that the phase dispersion is gradual and consistently applied in every sequence repetition. However, this issue will require further evaluation for other regions of the body such as the abdomen, where motion is a greater concern.

A more conventional approach for dark blood imaging of brain tumors is the 3D-VFA-FSE technique, which has been shown to be highly sensitive for small brain metastases (3). T₁ 3D-VFA-FSE has been included in recent consensus recommendations for tumor imaging (25). While further study is needed, our results suggest that there are significant drawbacks compared with uT₁RESS, including much lower SNR efficiency and tumor-to-background contrast, as well as longer minimum scan times. Other potential concerns include sensitivity to B₁ field inhomogeneity, blurring from T₂ decay if the echo train is overly long, and incomplete suppression of intravascular signals depending on the particular implementation (26).

This study had several limitations. Gold standard biopsies were only available in a minority of the cases. Scan times and spatial resolution varied for some of the imaging protocols, requiring normalization of the SNR. It would be preferable for future studies to keep these imaging parameters constant across imaging protocols. Residual signal was sometimes present in segments of small cortical veins. Concerns about persistent venous signal, along with other issues of potential clinical relevance, will need to be addressed in future studies.

In conclusion, T₁RESS represents a redesign of the traditional steady-state pulse sequence architecture. This novel MRI method enables the flexible modulation of T₁ weighting and provides the

unique feature that intravascular signals can be toggled on and off in contrast-enhanced scans. T₁RESS makes it possible to effectively use an MRI technique with improved SNR efficiency for cancer imaging. While this initial proof-of-concept study was not designed to determine the diagnostic accuracy of the technique, the combination of twofold improved tumor-to-background contrast and flexible control over intravascular signal has the potential to make T₁RESS a valuable clinical tool. The improvement in contrast should facilitate the detection of cancer at an earlier stage for the brain and other organs such as the liver, breast, and prostate than is possible with current MRI techniques. In addition, the combination of high SNR efficiency, short TR, and suppression of signal from macroscopic vessels may prove advantageous for dynamic contrast-enhanced evaluation of tumor perfusion.

T₁RESS could also prove beneficial for a range of nononcological applications. For instance, the sensitivity to contrast enhancement and suppression of intravascular signal with uT₁RESS could prove helpful for detecting active lesions of multiple sclerosis or evaluating vessel wall inflammation, whereas the high SNR efficiency of bT₁RESS could be leveraged to substantially reduce the contrast agent dosage or scan time needed for magnetic resonance angiography. However, further work is needed for sequence modeling, optimization, and clinical validation to realize the full potential of the technique.

MATERIALS AND METHODS

Experimental design

This study was approved by the hospital institutional review board with waiver of consent. Contrast-enhanced MRI of the brain was performed at 3 T (MAGNETOM Skyra and MAGNETOM Skyra^{fit}, Siemens Healthcare, Erlangen, Germany) in 54 adult subjects (ages, 19 to 88 years; 27 female) with suspected or known brain tumors. For contrast-enhanced MRI of the head, gadobutrol (0.1 mmol/kg) (Bayer, Berlin, Germany) was administered intravenously, followed by standard-of-care 2D fast spin echo and, in a subset of patients, 3D IR-SPGRE. Total scan duration for these postcontrast sequences ranged from approximately 6 to 13 min. Immediately following acquisition of these sequences, three additional postcontrast scans were typically obtained, consisting of balanced and unbalanced T₁RESS as well as an additional 3D spoiled GRE acquisition that was matched for scan time and spatial resolution with T₁RESS.

T₁RESS sequence design and scan parameters

To obtain T₁ weighting for a contrast-enhanced MRI scan, bSSFP traditionally incorporates a preparatory 90° saturation recovery (e.g., for first-pass contrast-enhanced perfusion imaging) or 180° IR RF pulse (e.g., for imaging of delayed myocardial enhancement). These preparatory RF pulses are followed by a waiting period of at least a few hundred milliseconds before data collection (27–30). The use of a single large flip angle preparatory RF pulse has several drawbacks: (i) It reduces the SNR; (ii) *k*-space lines acquired early in the echo train will have a markedly different amount of T₁ weighting from ones acquired later on, potentially causing a loss of contrast for small lesions; and (iii) the lengthy waiting period greatly diminishes the SNR efficiency compared with an unmodified bSSFP sequence, thereby increasing scan time.

The T₁RESS pulse sequence avoids these limitations by applying a rectangular-shaped, spatially nonselective partial saturation contrast-modifying (CM α) RF pulse at regular intervals (CM α TR)




Fig. 4. Pulse sequence comparisons in a patient with multiple breast cancer metastases to the brain. Axial (top) and coronal (bottom) 1-mm-thick axial multiplanar reformations for bT_1 RESS (left), uT_1 RESS (middle), and 3D spoiled GRE (right). With bT_1 RESS and 3D spoiled GRE, a minute metastasis (red arrow) is difficult to distinguish from enhancing blood vessels (green dashed arrows) running through the slice that have a similar appearance in cross section. However, the lesion can be unambiguously identified using uT_1 RESS because the signals from blood vessels and background tissues are well suppressed. Prominent left infratemporal contrast enhancement (blue open arrow) relates to a recent tumor resection.




Fig. 5. Patient with multiple metastases. (A) 3D inversion recovery spoiled GRE (IR-SPGRE). (B) 3D spoiled GRE. (C) uT_1 RESS. Two lesions (red arrows) are much more conspicuous with uT_1 RESS than with 3D IR-SPGRE or spoiled GRE, despite all sequences being acquired at the same spatial resolution. Multiple additional minute enhancing foci (such as the ones labeled with blue open arrows) are only visible with uT_1 RESS.

throughout the duration of a continuous 3D SSFP acquisition, without any waiting period (Fig. 1). For bT_1 RESS, the steady-state magnetization is stored along the z axis by a $\alpha/2(-)$ pulse immediately before each application of the $CM\alpha$ pulse, followed by a second $\alpha/2(+)$ pulse to restore the steady-state magnetization to its previous state (where α is the imaging flip angle). While the magnetization is stored along the z axis, the $CM\alpha$ RF pulse can be applied without disrupting the steady-state echo train. For uT_1 RESS, the $CM\alpha$

pulse is applied between phase-encoding segments without additional store/restore pulse pairs, while a weak gradient spoiler (20% of the default amplitude) is applied along the frequency-encoding direction between imaging RF pulses to provide a small degree of flow-related dephasing.

For both bT_1 RESS and uT_1 RESS, data are acquired using a Cartesian 3D k -space trajectory as a single shot along the phase-encoding direction, whereas the acquisition is segmented along the




Fig. 6. Pulse sequence comparisons in a patient with metastatic esophageal carcinoma. Comparison of T1 3D-VFA-FSE (left) with uT1RESS (right) using equal spatial resolution and scan time in a patient with multiple metastases from an esophageal carcinoma. Although both sequences effectively suppress intravascular signal, the contrast and CNR values for T1 3D-VFA-FSE were markedly inferior to uT1RESS (contrast = 0.37 versus 1.59, respectively; CNR = 51.0 versus 331.3, respectively).

3D partition-encoding direction. Typical sequence parameters included echo spacing of ≈ 2.9 ms, flip angle of the imaging RF pulse $\approx 50^\circ$, sampling bandwidth = 888 Hz per pixel, $CM\alpha$ flip angle = 75° , 7/8 slice partial Fourier, parallel acceleration factor = 2, and $CM\alpha$ TR ≈ 400 ms. A chemical shift-selective fat saturation RF pulse was applied along with each $CM\alpha$ RF pulse. Scan times were ≈ 1 min 45 s for two signal averages.

For T₁RESS and 3D spoiled GRE, a 3D slab was acquired in a sagittal orientation using a rectangular-shaped, spatially nonselective RF excitation. Spatial resolution was near isotropic with reconstructed slice thickness of 0.45 mm and in-plane spatial resolution of 0.5 mm. The 3D spoiled GRE acquisition used an echo spacing of 5.5 ms, flip angle of 11° , and sampling bandwidth of 395 Hz per pixel. Scan time for 3D spoiled GRE was ≈ 1 min 49 s. Standard-of-care 3D IR-SPGRE was acquired in an axial orientation with 1-mm³ isotropic spatial resolution, TR = 1900 ms, TI = 900 ms, TE = 2.4 ms, parallel acceleration factor = 2, sampling bandwidth = 250 Hz per pixel, and scan time = 4 min 30 s.

In 14 patients, both T1 3D-VFA-FSE and uT₁RESS were acquired using approximately 1-mm³ isotropic spatial resolution. T1 3D-VFA-FSE was acquired using default parameters (e.g., TR = 700 ms, echo train length = 44, sampling bandwidth = 435 Hz per pixel), except that the slice parallel acceleration factor was increased from 2 to 4 to reduce the scan time to 3.5 min. The number of signal averages was increased from 2 to 4 for uT₁RESS to match this scan time.

Signal measurement and statistical analysis

Region-of-interest signal measurements were obtained in brain lesions, in nearby normal brain tissue, in air, and in the superior sagittal sinus. Given that SNR per voxel was well above the Rose threshold of 4 to distinguish image features with certainty, it is unlikely that image noise plays much role in lesion visibility for the MRI scans used in this study. Therefore, we used a calculation analogous to Weber contrast, computed as $(SI_{\text{tumor}} - SI_{\text{normal}})/SI_{\text{normal}}$, as the primary metric for lesion visibility (31). In addition, the CNR was used as a secondary metric for lesion visibility, calculated as $0.655 \cdot (SI_{\text{tumor}} - SI_{\text{normal}})/SD_{\text{air}}$. SI_{tumor} and SI_{normal} are the mean sig-

nal intensities of the tumor and normal-appearing adjacent normal brain tissue, and SD_{air} is the standard deviation within air above the head. To normalize for the 2.57-fold longer scan time of the 3D IR-SPGRE sequence and the 2-fold longer scan time of T1 3D-VFA-FSE and 4-average uT₁RESS, the CNR was multiplied by $1/\sqrt{2.57}$ and $1/\sqrt{2}$, respectively. Quantitative measures were compared using Wilcoxon signed-rank tests. Statistical comparisons were done using the SciPy computing library (version 1.4.1, <https://scipy.org/sciypilib/>). Data were presented as mean \pm SD.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <http://advances.sciencemag.org/cgi/content/full/6/44/eabd1635/DC1>

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

1. K.-J. Langen, N. Galldiks, E. Hattingen, N. J. Shah, *Advances in neuro-oncology imaging. Nat. Rev. Neurol.* **13**, 279–289 (2017).
2. W. B. Pope, Brain metastases: Neuroimaging. *Handb. Clin. Neurol.* **149**, 89–112 (2018).
3. J. Park, J. Kim, E. Yoo, H. Lee, J.-H. Chang, E. Y. Kim, Detection of small metastatic brain tumors: Comparison of 3D contrast-enhanced whole-brain black-blood imaging and MP-RAGE imaging. *Invest. Radiol.* **47**, 136–141 (2012).
4. T. J. Fraum, D. R. Ludwig, M. R. Bashir, K. J. Fowler, Gadolinium-based contrast agents: A comprehensive risk assessment. *J. Magn. Reson. Imaging* **46**, 338–353 (2017).
5. B. A. Jung, M. Weigel, Spin echo magnetic resonance imaging. *J. Magn. Reson. Imaging* **37**, 805–817 (2013).
6. B. A. Hargreaves, Rapid gradient-echo imaging. *J. Magn. Reson. Imaging* **36**, 1300–1313 (2012).
7. O. Bieri, K. Scheffler, Fundamentals of balanced steady state free precession MRI. *J. Magn. Reson. Imaging* **38**, 2–11 (2013).
8. E. Kanal, K. Maravilla, H. A. Rowley, Gadolinium contrast agents for CNS imaging: Current concepts and clinical evidence. *AJNR Am. J. Neuroradiol.* **35**, 2215–2226 (2014).
9. L. Danielli, G. C. Riccitelli, D. Distefano, E. Prodi, E. Ventura, A. Cianfoni, A. Kaelin-Lang, M. Reinert, E. Pravatà, Brain Tumor-Enhancement Visualization and Morphometric Assessment: A Comparison of MPRAGE, SPACE, and VIBE MRI Techniques. *AJNR Am. J. Neuroradiol.* **40**, 1140–1148 (2019).
10. J. Frahm, Rapid FLASH NMR imaging. *Naturwissenschaften* **74**, 415–422 (1987).
11. K. Scheffler, S. Lehnardt, Principles and applications of balanced SSFP techniques. *Eur. Radiol.* **13**, 2409–2418 (2003).
12. G. B. Chavhan, P. S. Babyn, B. G. Jankharia, H.-L. Cheng, M. M. Shroff, Steady-state MR imaging sequences: Physics, classification, and clinical applications. *Radiographics* **28**, 1147–1160 (2008).
13. J. P. Wansapura, S. K. Holland, R. S. Dunn, W. S. Ball Jr., NMR relaxation times in the human brain at 3.0 tesla. *J. Magn. Reson. Imaging* **9**, 531–538 (1999).
14. B. Schmitz, T. Hagen, W. Reith, Three-dimensional true FISP for high-resolution imaging of the whole brain. *Eur. Radiol.* **13**, 1577–1582 (2003).
15. F. Fuchs, G. Laub, K. Othomo, TrueFISP—technical considerations and cardiovascular applications. *Eur. J. Radiol.* **46**, 28–32 (2003).
16. J. C. Carr, O. Simonetti, J. Bundy, D. Li, S. Pereles, J. P. Finn, Cine MR angiography of the heart with segmented true fast imaging with steady-state precession. *Radiology* **219**, 828–834 (2001).
17. R. R. Edelman, J. J. Sheehan, E. Dunkle, N. Schindler, J. Carr, I. Koktzoglou, Quiescent-interval single-shot unenhanced magnetic resonance angiography of peripheral vascular disease: Technical considerations and clinical feasibility. *Magn. Reson. Med.* **63**, 951–958 (2010).
18. Z. Fan, J. Sheehan, X. Bi, X. Liu, J. Carr, D. Li, 3D noncontrast MR angiography of the distal lower extremities using flow-sensitive dephasing (FSD)-prepared balanced SSFP. *Magn. Reson. Med.* **62**, 1523–1532 (2009).
19. O. Bieri, K. Scheffler, On the origin of apparent low tissue signals in balanced SSFP. *Magn. Reson. Med.* **56**, 1067–1074 (2006).
20. S. Yang, Y. Nam, M.-O. Kim, E. Y. Kim, J. Park, D.-H. Kim, Computer-aided detection of metastatic brain tumors using magnetic resonance black-blood imaging. *Invest. Radiol.* **48**, 113–119 (2013).
21. K. Sekihara, Steady-state magnetizations in rapid NMR imaging using small flip angles and short repetition intervals. *IEEE Trans. Med. Imaging* **6**, 157–164 (1987).
22. A. D. Elster, Gradient-echo MR imaging: Techniques and acronyms. *Radiology* **186**, 1–8 (1993).
23. M. Markl, J. Leupold, Gradient echo imaging. *J. Magn. Reson. Imaging* **35**, 1274–1289 (2012).

24. Z. Yu, T. Zhao, J. Assländer, R. Lattanzi, D. K. Sodickson, M. A. Cloos, Exploring the sensitivity of magnetic resonance fingerprinting to motion. *Magn. Reson. Imaging* **54**, 241–248 (2018).
25. T. J. Kaufmann, M. Smits, J. Boxerman, R. Huang, D. P. Barboriak, M. Weller, C. Chung, C. Tsien, P. D. Brown, L. Shankar, E. Galanis, E. Gerstner, M. J. van den Bent, T. C. Burns, I. F. Parney, G. Dunn, P. K. Brastianos, N. U. Lin, P. Y. Wen, B. M. Ellingson, Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. *Neuro Oncol.* **22**, 757–772 (2020).
26. B. Bapst, J. L. Amegnizin, A. Vignaud, P. Kuv, A. Maraval, E. Kalsoum, T. Tuilier, A. Benaissa, P. Brugieres, X. Leclerc, J. Hodel, Post-contrast 3D T1-weighted TSE MR sequences (SPACE, CUBE, VISTA/BRAINVIEW, isoFSE, 3D MVOX): Technical aspects and clinical applications. *J. Neuroradiol.* **47**, 358–368 (2020).
27. K. Scheffler, J. Winterer, M. Langer, J. Hennig, Contrast-enhanced angiography using T1-weighted TrueFISP. *Proc. Intl. Soc. Mag. Reson. Med.* **10**, (2002).
28. A. Huber, C. Hayes, B. Spannagl, J. Rieber, V. Klaus, S. O. Schoenberg, M. Reiser, B. J. Wintersperger, Phase-sensitive inversion recovery single-shot balanced steady-state free precession for detection of myocardial infarction during a single breathhold. *Acad. Radiol.* **14**, 1500–1508 (2007).
29. P. Kellman, A. E. Arai, Cardiac imaging techniques for physicians: Late enhancement. *J. Magn. Reson. Imaging* **36**, 529–542 (2012).
30. W. G. Schreiber, M. Schmitt, P. Kalden, O. K. Mohrs, K.-F. Kreitner, M. Thelen, Dynamic contrast-enhanced myocardial perfusion imaging using saturation-prepared TrueFISP. *J. Magn. Reson. Imaging* **16**, 641–652 (2002).
31. D. G. Pelli, P. Bex, Measuring contrast sensitivity. *Vision Res.* **90**, 10–14 (2013).

Acknowledgments

Funding: This work was supported by NIH grants R01 HL137920, R01 HL130093, and R01 EB027475. **Author contributions:** R.E. conceived the T₁RESS pulse sequence and was responsible for study design and data integrity. N.L. performed quantitative analysis and maintained a database. J.P. assisted with pulse sequence implementation. I.K. assisted with pulse sequence implementation and study design and performed statistical analysis. J.B. and R.M. contributed patients for the study and assisted with manuscript review. **Competing interests:** R.E. receives research support and royalties from Siemens Medical Solutions USA Inc. J.P. is an employee of Siemens Medical Solutions USA Inc. I.K. and R.E. are inventors on a provisional patent application related to this work filed by the NorthShore University HealthSystem, "System and Method for T1 Relaxation Enhanced Steady-State MRI" (filed 19 March 2020). The authors declare that they have no other competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. None of the material has been published or is under consideration for publication elsewhere. Additional data related to this paper may be requested from the authors.

Submitted 4 June 2020

Accepted 15 September 2020

Published 28 October 2020

10.1126/sciadv.abd1635

Citation: R. Edelman, N. Leloudas, J. Pang, J. Bailes, R. Merrell, I. Koktzoglou, Twofold improved tumor-to-brain contrast using a novel T1 relaxation-enhanced steady-state (T₁RESS) MRI technique. *Sci. Adv.* **6**, eabd1635 (2020).